Source: Heather Leah, WRAL, 8/2/20


On Sunday, Duke announced that the Duke Human Vaccine Institute (DHVI) was given approval for a clinical trial that, if effective, could advance COVID care until a vaccine can be developed. The approval means the DHVI can launch Phase 1 of the clinical trial for one of the most promising antibody treatments for COVID-19. "This would be a temporary treatment until a vaccine is developed," said Duke Today in a statement.

For more of this story, click here.